Haemonetics Surges with Q1 Growth | Business and Finance News

Haemonetics kicks off FY27 with a strong Q1, reporting $339M in revenue—a 6% year-over-year jump—and adjusted EPS up 4% to $1.14. Growth is fueled by smart investments across portfolio, operations, and sales. MedSurg rose 6%, Interventional Technologies rebounded 3% thanks to vascular closure, and Apheresis surged 5% (6% organically) to $191M, driven by plasma’s 8% organic growth and the successful Persona PLUS system. The company is raising full-year guidance to 5–8% reported and 4–7% organic growth, signaling confidence in ongoing segment momentum. With healthy cash flow, Haemonetics plans to reinvest in innovation, strengthen its balance sheet, and pursue strategic opportunities—all while staying disciplined on deleveraging. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/2c77f3b892bea1ba